Hengrui Pharma Presents Oncology Advances at ASCO
Analysis based on 7 articles · First reported Jun 01, 2026 · Last updated Jun 08, 2026
The positive clinical trial results presented by Jiangsu Hengrui across various cancer types are expected to boost investor confidence in the company's oncology pipeline, potentially leading to an increase in its stock price. These advancements could also impact the broader pharmaceutical market by introducing new treatment options and setting new benchmarks in cancer care. The market will likely react positively to the potential for new revenue streams for Jiangsu Hengrui and improved patient outcomes.
Jiangsu Hengrui presented over 90 oncology studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant progress in various cancer treatments. Key findings include a 57.5% pathological complete response rate for camrelizumab combined with chemotherapy in triple-negative breast cancer (HELEN-Trio 011 study led by Professor Zhenzhen Liu), and a noninferior chemotherapy-de-escalated regimen for HER2-positive early breast cancer (HELEN HER-013 study). In gastrointestinal cancers, trastuzumab rezetecan showed a median progression-free survival of 5.5 months in advanced colorectal cancer (HORIZON-CRC01 study co-led by Professor Jin Li and Professor Ying Yuan), and the 'Camrelizumab + Apatinib' regimen significantly prolonged PFS in liver cancer (CARES-336 study co-led by Academician Sima Yi s Liaodong campaign and Professor Shukui Qin). For urological cancers, fluzoparib combined with abiraterone acetate and prednisone extended radiographic PFS to 24.8 months in metastatic castration-resistant prostate cancer (FUZUPRO study led by Professor Dingwei Ye). Additionally, a novel antiemetic drug developed by Jiangsu Hengrui demonstrated significantly higher complete response rates in supportive cancer care (PROTECT study co-led by Professor Zhang Rui and Professor Yuhong Li). These presentations underscore Jiangsu Hengrui's ongoing investment in innovative drug development and its expanding oncology pipeline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard